Comparison of Patient Satisfaction with Two Different Etanercept Delivery Systems. A Randomised Controlled Study in Patients with Rheumatoid Arthritis

Overview

Journal Z Rheumatol

Publisher Springer

Specialty Rheumatology

Date 2012 Sep 8

PMID 22956167

Citations 6

Authors

U Muller-Ladner

R M Flipo

P Vincendon

Y Brault

D Kielar

Affiliations

Soon will be listed here.

Abstract

The objective of this study was to investigate patients' perceptions of the acceptability of two devices delivering etanercept for rheumatoid arthritis (RA) treatment and to explore whether specific patients' attributes are associated with device preferences. Two similar multicenter, open-label, randomised, parallel-design studies were conducted in a total of 13 European countries. A total of 640 adult patients with RA were randomised to receive etanercept 50 mg once-weekly subcutaneously for 12 weeks in either a pre-filled syringe (PFS) or a pre-filled pen (PFP). Patient satisfaction at week 12 was measured on a 0- to 10-point Likert scale (primary endpoint). The study was powered to demonstrate non-inferiority of a PFP over PFS for the primary endpoint. At week 12, mean patient satisfaction was 8.3 (± 2.4) points in the pen group and 7.2 (± 2.6) points in the syringe group. Non-inferiority and even superiority of the pen over the syringe was demonstrated. In conclusion, this study showed higher patient satisfaction in the group of patients injecting etanercept with a PFP compared with the group of patients using a PFS.

Citing Articles

International Survey to Evaluate Current Options for Subcutaneous Injection of Methotrexate (MTX) and a New Button-Free MTX Autoinjector.

Muller-Ladner U, Edwards C, Erkens A Patient Prefer Adherence. 2024; 18:579-590.

PMID: 38463400 PMC: 10924829. DOI: 10.2147/PPA.S440818.

Monoclonal antibody and protein therapeutic formulations for subcutaneous delivery: high-concentration, low-volume vs. low-concentration, high-volume.

Desai M, Kundu A, Hageman M, Lou H, Boisvert D MAbs. 2023; 15(1):2285277.

PMID: 38013454 PMC: 10793682. DOI: 10.1080/19420862.2023.2285277.

Usability Study of PF-06410293, an Adalimumab Biosimilar, by Prefilled Pen: Open-Label, Single-Arm, Sub-Study of a Phase 3 Trial in Patients with Rheumatoid Arthritis.

Fleischmann R, Bock A, Zhang W, Godfrey C, Vranic I, Cronenberger C Rheumatol Ther. 2022; 9(3):839-850.

PMID: 35304684 PMC: 9127023. DOI: 10.1007/s40744-022-00439-8.

Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross-sectional observational study.

Lee S, Kim Y, Lee S, Lee S, Kim Y, Jeon J Int J Rheum Dis. 2022; 25(5):523-531.

PMID: 35187866 PMC: 9303183. DOI: 10.1111/1756-185X.14304.

A portfolio of biologic self-injection devices in rheumatology: how patient involvement in device design can improve treatment experience.

van den Bemt B, Gettings L, Domanska B, Bruggraber R, Mountian I, Kristensen L Drug Deliv. 2019; 26(1):384-392.

PMID: 30905213 PMC: 6442222. DOI: 10.1080/10717544.2019.1587043.

References

Weinblatt M, Schiff M, Ruderman E, Bingham 3rd C, Li J, Louie J . Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum. 2008; 58(7):1921-30. DOI: 10.1002/art.23493. View

Kivitz A, Cohen S, Dowd J, Edwards W, Thakker S, Wellborne F . Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH trial. Clin Ther. 2006; 28(10):1619-29. DOI: 10.1016/j.clinthera.2006.10.006. View

van den Bemt B, van den Hoogen F, Benraad B, Hekster Y, van Riel P, van Lankveld W . Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol. 2009; 36(10):2164-70. DOI: 10.3899/jrheum.081204. View

Moreland L, Schiff M, Baumgartner S, Tindall E, Fleischmann R, Bulpitt K . Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999; 130(6):478-86. DOI: 10.7326/0003-4819-130-6-199903160-00004. View

den Broeder A, Creemers M, van Gestel A, Van Riel P . Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. Rheumatology (Oxford). 2002; 41(6):638-42. DOI: 10.1093/rheumatology/41.6.638. View

Fraenkel L, Bogardus S, Concato J, Felson D, Wittink D . Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis. 2004; 63(11):1372-8. PMC: 1754807. DOI: 10.1136/ard.2003.019422. View

Rubin R, Peyrot M . Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care. 2004; 27(10):2495-7. DOI: 10.2337/diacare.27.10.2495. View

Chilton F, Collett R . Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskeletal Care. 2007; 6(1):1-14. DOI: 10.1002/msc.110. View

Lefevre-Colau M, Fayad F, Rannou F, Fermanian J, Coriat F, Mace Y . Frequency and interrelations of risk factors for chronic low back pain in a primary care setting. PLoS One. 2009; 4(3):e4874. PMC: 2654108. DOI: 10.1371/journal.pone.0004874. View

10.

Combe B . Update on the use of etanercept across a spectrum of rheumatoid disorders. Biologics. 2009; 2(2):165-73. PMC: 2721350. DOI: 10.2147/btt.s1379. View

11.

Weidmann E, Unger J, Blair S, Friesen C, Hart C, Cady R . An open-label study to assess changes in efficacy and satisfaction with migraine care when patients have access to multiple sumatriptan succinate formulations. Clin Ther. 2003; 25(1):235-46. DOI: 10.1016/s0149-2918(03)90031-2. View

12.

Maradit-Kremers H, Nicola P, Crowson C, OFallon W, Gabriel S . Patient, disease, and therapy-related factors that influence discontinuation of disease-modifying antirheumatic drugs: a population-based incidence cohort of patients with rheumatoid arthritis. J Rheumatol. 2005; 33(2):248-55. View

13.

Schwartzman S, Morgan Jr G . Does route of administration affect the outcome of TNF antagonist therapy?. Arthritis Res Ther. 2004; 6 Suppl 2:S19-23. PMC: 2833461. DOI: 10.1186/ar996. View

14.

Hibbard J, Stockard J, Mahoney E, Tusler M . Development of the Patient Activation Measure (PAM): conceptualizing and measuring activation in patients and consumers. Health Serv Res. 2004; 39(4 Pt 1):1005-26. PMC: 1361049. DOI: 10.1111/j.1475-6773.2004.00269.x. View

15.

Paul C, Stalder J, Thaci D, Vincendon P, Brault Y, Kielar D . Patient satisfaction with injection devices: a randomized controlled study comparing two different etanercept delivery systems in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2011; 26(4):448-55. DOI: 10.1111/j.1468-3083.2011.04093.x. View

16.

Sourial N, Wolfson C, Zhu B, Quail J, Fletcher J, Karunananthan S . Correspondence analysis is a useful tool to uncover the relationships among categorical variables. J Clin Epidemiol. 2009; 63(6):638-46. PMC: 3718710. DOI: 10.1016/j.jclinepi.2009.08.008. View

17.

Scarpato S, Antivalle M, Favalli E, Nacci F, Frigelli S, Bartoli F . Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). Rheumatology (Oxford). 2009; 49(2):289-94. DOI: 10.1093/rheumatology/kep354. View

18.

Zigmond A, SNAITH R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x. View

19.

Williams E, Edwards C . Patient preferences in choosing anti-TNF therapies-R1. Rheumatology (Oxford). 2006; 45(12):1575-6. DOI: 10.1093/rheumatology/kel369. View

20.

Briand S, Beresniak A, Nguyen T, Yonli T, Duru G, Kambire C . Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach. PLoS Negl Trop Dis. 2009; 3(7):e483. PMC: 2704869. DOI: 10.1371/journal.pntd.0000483. View